Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

The whole brain radiotherapy is a safe and effective backbone in primary central nervous system lymphoma: A 23-year real-world experience

Haiyan Yang, Cong Li, Tao Lei, XI Chen, Haifeng Yu

Blood (2025) 146 (Supplement 1): 2752.

https://doi.org/10.1182/blood-2025-2752

Published: 2025

Journal Articles

Deciphering tph cells as prognostic drivers of angioimmunoblastic T-cell lymphoma

Haiyan Yang, Kaiyang Ding, Cong Li, Weihao Zhuang, Yangjie Ru, Jieyu Xu, Xinchen Wang, XI Chen, Xiaowu Dong, Tao Lei, Jialiang Lu

Blood (2025) 146 (Supplement 1): 5305.

https://doi.org/10.1182/blood-2025-5305

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Blood (2025) 146 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2025-3587

Published: 2025

Journal Articles

USP28 inhibition upregulates CD20 via c-myc suppression and synergizes with anti-CD20 immunotherapy in B-cell lymphomas

Jieyu Xu, Shihui Mao, Pumin Zhang, Hong-Hu Zhu, Jiang-Jiang Qin, Haiyan Yang

Blood (2025) 146 (Supplement 1): 5093.

https://doi.org/10.1182/blood-2025-5093

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma

Jieyu Xu, Haifeng Yu, Cong Li, XI Chen, Shuiyun Han, Shuailing Peng, Tao Lei, Haiyan Yang

Blood (2025) 146 (Supplement 1): 7103.

https://doi.org/10.1182/blood-2025-7103

Published: 2025

Journal Articles

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Blood (2025) 146 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2025-1796

Published: 2025

Journal Articles

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Blood (2025) 146 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2025-1957

Published: 2025

Journal Articles

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Blood (2025) 146 (Supplement 1): 1919.

https://doi.org/10.1182/blood-2025-1919

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2025-3896

Published: 2025

Journal Articles

Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study

Yu-Ran Qiu, Ming-Ci Cai, Wenyu Li, Haiyan Yang, Jing Wang, Li Wang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3649.

https://doi.org/10.1182/blood-2025-3649

Published: 2025

Journal Articles

Novel gsdmd agonist dmb induces synergistic pyroptosis and apoptosis in diffuse large B-cell lymphoma

Shihui Mao, Fangrong Shi, Jieyu Xu, XI Chen, Jialiang Lu, Xiaowu Dong, Haiyan Yang

Blood (2025) 146 (Supplement 1): 6822.

https://doi.org/10.1182/blood-2025-6822

Published: 2025

Journal Articles

Upregulation of extracellular matrix remodeling gene set drives progression and poor prognosis in angioimmunoblastic T-cell lymphoma.

Jieyu Xu, Weihao Zhuang, Yangjie Ru, Cong Li, XI Chen, Yiqun Chu, Fangrong Shi, Haifeng Yu, Huilin Peng, Jinxin Che, Tao Lei, Jialiang Lu, Haiyan Yang

Blood (2025) 146 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2025-1874

Published: 2025

Journal Articles

TCF-1 overexpression enhances CD19.CAR-T cell potency by attenuating activation-induced cell death

Qian Chen, Hao Yao, Xiyue Xu, Jialiang Lu, Haiyan Yang

Blood (2025) 146 (Supplement 1): 4126.

https://doi.org/10.1182/blood-2025-4126

Published: 2025

Journal Articles

Development of a NO probe cell imaging method based on CD58 expression in diffuse large B-cell lymphoma and as a tool to predict CAR-T efficacy

Xiyue Xu, Huan Zhou, Jialiang Lu, XI Chen, Yangjie Ru, Weihao Zhuang, Cong Li, Jieyu Xu, Qian Chen, Yiqun Chu, Xiaowu Dong, Tao Lei, Jinxin Che, Haiyan Yang

Blood (2025) 146 (Supplement 1): 2551.

https://doi.org/10.1182/blood-2025-2551

Published: 2025

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2024) 144 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2024-197877

Published: 2024

Journal Articles

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Zheng Song, Ying Cheng, Haiyan Yang, Liling Zhang, Liqun Zou, Ye Guo, Junning Cao, Huiqiang Huang, Zhao Wang, Sha Huang, Yiqian Fang, Jiaoyan Lyu, Keshu Zhou, Huilai Zhang

Blood (2024) 144 (Supplement 1): 986.

https://doi.org/10.1182/blood-2024-193167

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xi Chen, Xianggui Yuan, Haiyan Yang, Wenbin Qian, Miao Hu, Yanping Zhang, Xinglu Zhou

Blood (2024) 144 (Supplement 1): 6482.

https://doi.org/10.1182/blood-2024-201166

Published: 2024

Journal Articles

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

Yuqin Song, Haiyan Yang, Youchao Jia, Lixia Sheng, Lijuan Deng, Xi Chen, Yongjing Tang, Xifang Liu, Sijun Liu, Min Wei, Feng Li

Blood (2024) 144 (Supplement 1): 6481.

https://doi.org/10.1182/blood-2024-199342

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The whole brain radiotherapy is a safe and effective backbone in primary central nervous system lymphoma: A 23-year real-world experience

Deciphering tph cells as prognostic drivers of angioimmunoblastic T-cell lymphoma

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

USP28 inhibition upregulates CD20 via c-myc suppression and synergizes with anti-CD20 immunotherapy in B-cell lymphomas

Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: A prospective, multicenter, Phase Ⅱ study

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study

Novel gsdmd agonist dmb induces synergistic pyroptosis and apoptosis in diffuse large B-cell lymphoma

Upregulation of extracellular matrix remodeling gene set drives progression and poor prognosis in angioimmunoblastic T-cell lymphoma.

TCF-1 overexpression enhances CD19.CAR-T cell potency by attenuating activation-induced cell death

Development of a NO probe cell imaging method based on CD58 expression in diffuse large B-cell lymphoma and as a tool to predict CAR-T efficacy

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Phase 1/2 Studies of DZD8586, a Non-Covalent BBB Penetrant LYN/BTK Dual Inhibitor, in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia (CLL) and Other B-Cell Non-Hodgkin Lymphoma (B-NHL)

Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Preliminary Efficacy and Safety of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory (R/R) Central Nervous System Lymphoma or Treatment-Naïve (TN) Central Nervous System Lymphoma, Results from the Phase Ib Combination Part of HZ-a-018-102 Study

MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase Ⅰ, Dose-Escalation Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only